e-ISSN: 2394-2967
logo

British Journal of Medical and Health Research

LoginTrack

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

Volume 2, Issue 5 - 2015 (May 2015 Issue 5)

Volume 2 Issue 5 Cover

Issue Details:

Volume 2 Issue 5
Published:Invalid Date

Editorial: May 2015 Issue 5

Welcome to the 2015 issue of British Journal of Medical and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr Hemangi J Patel
Editor-in-Chief
British Journal of Medical and Health Research

Articles in This Issue

Showing 4 of 4 articles
Research PaperID: BJMHR0205001

Lumefantrine: A Review on Analytical Methods

D Mounika, R Shanmugam, A M Krishna, A Kirthi, M S Prathyusha, G S Rani

Lumefantrine is a antimalarial drug which is widely used in malaria endemic areas. For anti-malaria therapy Lumefantrine is used in combination with Artemether under the brand name of co-artem. Lumefantrine have an endoperoxide bridge, which interferes with haeme polymerization critical detoxifying pathway for the malaria parasite and also inhibiting in the nucleic acid and protein synthesis within the parasite as a secondary action. The Lumefantrine-Artemether combination is the first line therapy recommended by Brazilian Health Ministry to the falciparum malaria treatment (Brasil, 2006) now a days. This article examines published analytical methods reported so far in the literature for the determination of Lumefantrine in biological samples and pharmaceutical formulations; they include various techniques like spectrophotometer, high pressure liquid chromatography, liquid chromatography-electrospray ionization tandem mass spectrometry and high-performance thin layer chromatography.

LumefantrineAnalytical methodsAnti malarial
4,168 views
1,287 downloads

Contributors:

 D Mounika
,
 R Shanmugam
,
 A M Krishna
,
 A Kirthi
,
 M S Prathyusha
,
 G S Rani
Research PaperID: BJMHR0205002

Lipid Profile in Sudanese Patients with Polycystic Ovary Syndrome

AbdElkarim A Abdrabo, Salwa M Hassan, Gad A Modawe

Polycystic ovarian syndrome (PCOS) is associated with dyslipidaemia and may render the affected women “at risk” of developing cardiovascular disease. Objective of this study was to evaluate lipid parameters in Sudanese Patients with Polycystic Ovary Syndrome. The study was case control hospital based carried, out on 32 diagnosed PCOS subjects aged (18-35 years) and 32 age-matched healthy women. Blood samples were collected in a fasting state and lipid parameters were estimated by Biosystem Kits using Spectrophotometer. The mean ± standard deviation of total cholesterol, triglycerides, LDL, VLDL, HDL respectively in cases were (194±36.3, 95.8±29.0, 128.4±32.1, 19.1±5.8, 47.1±14.1). while the mean and standard deviation of total cholesterol, triglycerides, LDL, VLDL, HDL respectively in control were (166.22±16.7, 86.1±12.6, 89.9±21.2, 17.22±2.53, 59.5±12.3). There were significant elevation in most lipid profile. The study concluded that, most lipid profile were significantly increased except triglycerides and VLDL.

Polycystic ovarian syndromelipid profileSudanese.
4,250 views
1,454 downloads

Contributors:

 AbdElkarim A Abdrabo
,
 Salwa M Hassan
,
 Gad A Modawe
Research PaperID: BJMHR0205003

Formulation and Evaluation of Atenolol Topical Gel: A Novel Approach for Penetration Enhancement Formulation

Swapna Porandla, Priyanka P, R Sunil

Transdermal gel has gained more and more importance because the gel based formulations are better percutaneously absorbed than other topical dosage forms. Hypertension is defined by an elevation of the systolic or diastolic threshold or both. Atenolol, a class III molecule is a selective cardio-vascular β-blocker, which block the synthesis of Adenylate Cyclase there by prevents the formation of intra cellular messenger, cyclic AMP responsible for the activation of various protein kinases responsible for phosphorylation. The present work involve in the formulation of Atenolol Transdermal gels by dispersion method with different ratios of polymers for the sustained release of the drug through Stratum Corneum using Di-Methyl Sulphoxide, as penetration enhancer for the treatment of hypertension. All the formulations were evaluated for physico-chemical parameters and all the values were obtained within the limits. The in-vitro diffusion studies were carried out against dialysis membrane and ex-vivo permeation studies using albino rat abdominal skin by Franz diffusion cells. On hydration, osmotic pressure breaks & drug release follow zero order. Among fifteen formulations, In-vitro % Drug Release values of the optimized formulations were figured to be 98.22, 96.42 & 94.62 for F2, F11 & F13 respectively. The drug permeated/cm2 through skin was also determined by flux value for optimized formulations F2, F11 and F13 was 0.073 gmH-1cm-2, 0.069 gmH-1cm-2 and 0.082 gmH-1cm-2 respectively.

Franz diffusion cellDi-Methyl SulphoxideDialysis MembraneAlbino Rats
4,720 views
1,397 downloads

Contributors:

 Swapna Porandla
,
 Priyanka P
,
 R Sunil
Research PaperID: BJMHR0205004

Formulation and Evaluation of Effervescent Tablet of Sildenafil Citrate and Aspirin in Combination

Zeel J Patel, Vipul Patel

The study was undertaken with an aim to formulate effervescent tablet of sildenafil citrate and aspirin in combination to achieve the immediate release and fast action of sildenafil citrate on the body with shorter period of the time and to overcome the side effect of the sildenafil citrate by simultaneous release of aspirin. A 32 full factorial design was applied and it revealed that the bicarbonate source (X1) and concentration of binder (X2) significantly affected the independent variables effervescence time (Y1) and hardness (Y2). The optimized formulation having citric acid 23.65 %, tartric acid 6.30 %, sodium bicarbonate 37.85 %, potassium bicarbonate 12.61 % with binder concentration 2% and hardness adjusted to 3 kg/cm2. From among the 9 batches (D1 – D9) the D3 batch have desirable property, less effervescence time, enough hardness and immediate release profile.

Sildenafil CitrateAspirineEffervecence Tablet
4,496 views
1,369 downloads

Contributors:

 Zeel J Patel
,
 Vipul Patel

Related Issues

Volume 13, Issue 1

2026 • 2 articles

Volume 12, Issue 12

2025 • 2 articles

Volume 12, Issue 11

2025 • 2 articles

Volume 12, Issue 10

2025 • 2 articles